Artificial intelligence quantitative analysis reveals the effect of interleukin-6 injury in 2019 novel coronavirus B.1.617.2

doi:10.19871/j.cnki.xfcrbzz.2021.03.002

Abstract

Abstract: Objective To investigate the correlation of lung injury caused by interleukin-6 (IL-6) in 2019 novel coronavirus (2019-nCoV) B.1.617.2. It is suggested that the level of IL-6 should be detected in time and intervention should be carried out in advance in order to reduce the risk of severe pneumonia. Methods A retrospective study was conducted to collect 123 patients infected with 2019-nCoV B.1.617.2 from the Guangzhou Eighth People's Hospital, Guangzhou Medical University, in May 21 to June 21, 2021. There were 105 mild cases and 18 severe cases. The clinical characteristics, inflammatory index levels, IL-6 and artificial intelligence(AI) lung injury degree of the two groups were analyzed. Results The mean value of age, peak value of procalcitonin (PCT), peak value of serum IL-6 and peak value of pulmonary injury measured by AI in patients with 2019-nCoV B.1.617.2 strain were higher than those in patients with mild disease group (P<0.05). The mean value of serum IL-6 in patients with severe disease group was （197.28±105.70）pg/ml. The peak value of lung injury measured by AI accounted for （36.21±14.91）%, and the main imaging features of lung injury were multiple ground glass opacity and consolidation in bilateral lungs. Conclusion High expression of IL-6 is a potential immune risk factor for lung injury in patients with 2019-nCoV B.1.167.2 strain. AI quantitative analysis helps to determine the severity of pneumonia in patients, intervention as early as possible. In order to reduce the risk of severe pneumonia.

Key words: 2019 novel coronavirus, Virus variant, Pneumonia, Interleukin-6, Artificial intelligence

Gan Qingxin, Liu Jinxin, Yang Yanhong, Hu Tianli, Zhang Lieguang, Huang Deyang, Li Meiyu. Artificial intelligence quantitative analysis reveals the effect of interleukin-6 injury in 2019 novel coronavirus B.1.617.2[J]. Electronic Journal of Emerging Infectious Diseases, 2021, 6(3): 172-176.

References

[1] SHEIKH A, TAYLOR B, MCMENAMIN C, et al.SARS-Cov-2 Delta VOC in Scotland:demographics,risk of hospital admission,and vaccine effecticeness[J].Lancet, 2021,397(10293)2461-2462.
[2] SOHRABI C, ALSAFI Z, N O'NEILL, et al. World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19)[J]. Int J Surg, 2020,(76):71-76.
[3] LIAO BL, LIU ZP, TANG LB, et al.Longitudinal analysis reveals the effect of interleukin-6 on persistent pulmonary injuryin COVID-19[J]. Int J Med Sci, 2021, 18(1):29-41.
[4] 中华人民共和国国家卫生健康委员会. 新型冠状病毒肺炎防控方案(第八版)[EB/OL].[2021-05-14].http://www.gov.cn/xinwen/2021-05/14/content_5606469.htm.
[5] WU A, PENG Y, HUANG B, et al.Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China[J]. Cell Host Microbe, 2020, 27(3): 325-328.
[6] LETKO M, MARZI A, MUNSTER V.Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses[J]. NAT MICROBIOL,2020,2(5):562-569.
[7] 江芮, 刘晋新, 张烈光,等. 8组家族聚集性发病的COVID-19胸部CT表现及转归[J/CD]. 新发传染病电子杂志, 2020,5(02):87-90.
[8] 宋玉燕,黄长先,周璐,等. 中西医结合疗法治疗31例重型新型冠状病毒肺炎临床疗效分析[J/CD]. 新发传染病电子杂志, 2020, 5(4):239-242.
[9] 林绿, 刘夏, 吴念宁,等. 血清心肌损伤指标变化与新型冠状病毒肺炎重症风险的相关性研究[J/CD]. 新发传染病电子杂志, 2020,5(3):159-164.
[10] XU X, YU C, QU J, et al. Imaging and clinical features of patients with2019 novel coronavirus SARS-CoV-2. EUR J NUCL MED MOL I,2020(8):1-6.
[11] 孙昀, 孙伟, 叶珺, 等. 168例新型冠状病毒肺炎患者临床特点及重症进展的影响因素分析[J]. 中华急诊医学杂志, 2020, 29(7):901-907.
[12] 占婷婷, 郑海鹏, 麦玉珍, 等. 新型冠状病毒肺炎患者血清学动态演变与病情的关系分析[J]. 广东医学, 2020, 41(9):878-883.
[13] 石亚玲, 区静怡, 陈星, 等. 多种炎症指标在2019新型冠状病毒肺炎的表达水平临床应用价值[J]. 中华检验医学杂志,2020,43(00):E013-E013.
[14] 降钙素原在成人下呼吸道感染性疾病分级管理中的应用专家共识组. 降钙素原在成人下呼吸道感染性疾病分级管理中的应用专家共识[J]. 中华急诊医学杂志, 2021, 30(4):393-401.
[15] QIN C, ZHOU L, HU Z, et al.Dysregulation of immune response in patients with COVID-19 in Wuhan, China[J]. Clin Infect Dis, 2020, 71(15):762-768.
[16] CHEN G, WU D, GUO W, et al.Clinical and immunological features of severe and moderate coronavirus disease 2019[J]. J Clin Invest, 2020,130(5):2620-2629.
[17] CHEN N, ZHOU M, DONG X, et al.Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study[J]. Lancet, 2020, 395(10223):507-513.
[18] HUANG C, WANG Y, LI X, et al.Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020,395(10223):497-506.
[19] 单鸿伟, 吕政, 肖燕, 等. 危重型新型冠状病毒肺炎有创机械通气患者炎性细胞因子水平的变化分析[J]. 中华危重病急救医学, 2020, 32(9):1051-1055.